Efficacy of Contemporary Chemotherapy in Stage IIIC Endometrial Cancer: a Histologic Dichotomy

Overview

Journal Gynecol Oncol

Date 2014 Jan 18

PMID 24434057

Citations 17

Authors

Jamie N Bakkum-Gamez

Andrea Mariani

Sean C Dowdy

Amy L Weaver

Michaela E McGree

Janice R Martin

Gary L Keeney

Aminah Jatoi

Bobbie S Gostout

Karl C Podratz

Affiliations

Soon will be listed here.

Abstract

Background: Treatment failures in stage IIIC endometrial carcinoma (EC) are predominantly due to occult extrapelvic metastases (EPM). The impact of chemotherapy on occult EPM was investigated according to grade (G), G1/2EC vs G3EC.

Methods: All surgical-stage IIIC EC cases from January 1, 1999, through December 31, 2008, from Mayo Clinic were included. Patient-, disease-, and treatment-specific risk factors were assessed for association with overall survival, cause-specific survival, and extrapelvic disease-free survival (DFS) using Cox proportional hazards regression.

Results: 109 cases met criteria, with 92 (84%) having systematic lymphadenectomy (>10 pelvic and >5 paraaortic lymph nodes resected). In patients with documented recurrence sites, occult EPM accounted for 88%. Among G1/2EC cases (n=48), the sole independent predictor of extrapelvic DFS was grade 2 histology (hazard ratio [HR], 0.28; 95% CI, 0.08-0.91; P=.03) while receipt of adjuvant chemotherapy approached significance (HR 0.13; 95% CI, 0.02, 1.01; P=.0511). The 5-year extrapelvic DFS with and without adjuvant chemotherapy was 93% and 54%, respectively (log-rank, P=.02). Among G3EC (n=61), the sole independent predictor of extrapelvic DFS was lymphovascular space involvement (HR, 2.63; 95% CI, 1.16-5.97; P=.02). Adjuvant chemotherapy did not affect occult EPM in G3EC; the 5-year extrapelvic DFS for G3EC with and without adjuvant chemotherapy was 43% and 42%, respectively (log-rank, P=.91).

Conclusions: Chemotherapy improves extrapelvic DFS for stage IIIC G1/2EC but not stage IIIC G3EC. Future efforts should focus on prospectively assessing the impact of chemotherapy on DFS in G3EC and developing innovative phase I and II trials of novel systemic therapies for advanced G3EC.

Citing Articles

Local Disease-Free Survival and Disease-Free Survival in Locally Advanced Cervical Cancer Diagnosed and Treated in Bihor County, Romania.

Molnar O, Mihutiu S, Ilea C, Vesa A, Straciuc O, Nemeth N Cureus. 2024; 16(7):e65629.

PMID: 39205752 PMC: 11350524. DOI: 10.7759/cureus.65629.

Effects of Adjuvant Radiation Plus Chemotherapy on Survival Outcomes in Stage III C Endometrial Cancer According to Histology: Analysis of Data from the Surveillance, Epidemiology, and End Results Database.

Kou J, Yan G, Xiao L, Wei N, Ren H, Xu J Technol Cancer Res Treat. 2023; 22:15330338231208610.

PMID: 37926997 PMC: 10629328. DOI: 10.1177/15330338231208610.

ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.

Gonzalez-Bosquet J, Weroha S, Bakkum-Gamez J, Weaver A, McGree M, Dowdy S PLoS One. 2022; 17(12):e0278408.

PMID: 36454788 PMC: 9714733. DOI: 10.1371/journal.pone.0278408.

Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy.

Otsuka I Cancers (Basel). 2022; 14(18).

PMID: 36139675 PMC: 9497184. DOI: 10.3390/cancers14184516.

Open Surgery including Lymphadenectomy without Adjuvant Therapy for Uterine-Confined Intermediate- and High-Risk Endometrioid Endometrial Carcinoma.

Otsuka I, Matsuura T, Mitani T, Otsuka K, Kanamoto Y Curr Oncol. 2022; 29(5):3728-3737.

PMID: 35621688 PMC: 9139559. DOI: 10.3390/curroncol29050298.

References

Aalders J, Thomas G . Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol. 2006; 104(1):222-31. DOI: 10.1016/j.ygyno.2006.10.013. View

Secord A, Havrilesky L, Bae-Jump V, Chin J, Calingaert B, Bland A . The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007; 107(2):285-91. DOI: 10.1016/j.ygyno.2007.06.014. View

Hall B, Hamilton B, Richards K, Bilimoria K, Cohen M, Ko C . Does surgical quality improve in the American College of Surgeons National Surgical Quality Improvement Program: an evaluation of all participating hospitals. Ann Surg. 2009; 250(3):363-76. DOI: 10.1097/SLA.0b013e3181b4148f. View

Scholten A, van Putten W, Beerman H, Smit V, Koper P, Lybeert M . Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005; 63(3):834-8. DOI: 10.1016/j.ijrobp.2005.03.007. View

Kilgore L, Partridge E, Alvarez R, Austin J, SHINGLETON H, Noojin 3rd F . Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995; 56(1):29-33. DOI: 10.1006/gyno.1995.1005. View

Klopp A, Jhingran A, Ramondetta L, Lu K, Gershenson D, Eifel P . Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009; 115(1):6-11. DOI: 10.1016/j.ygyno.2009.06.035. View

Rose P, Cha S, Tak W, Fitzgerald T, Reale F, HUNTER R . Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1992; 24(2):229-33. DOI: 10.1016/0360-3016(92)90676-9. View

Secord A, Geller M, Broadwater G, Holloway R, Shuler K, Dao N . A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol. 2012; 128(1):65-70. DOI: 10.1016/j.ygyno.2012.10.010. View

Mariani A, Dowdy S, Cliby W, Gostout B, Jones M, Wilson T . Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008; 109(1):11-8. PMC: 3667391. DOI: 10.1016/j.ygyno.2008.01.023. View

10.

Mundt A, Murphy K, Rotmensch J, Waggoner S, Yamada S, Connell P . Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001; 50(5):1154-60. DOI: 10.1016/s0360-3016(01)01590-5. View

11.

Ayeni T, Bakkum-Gamez J, Mariani A, McGree M, Weaver A, Haddock M . Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013; 129(3):478-85. DOI: 10.1016/j.ygyno.2013.03.011. View

12.

McMeekin D, Lashbrook D, Gold M, Johnson G, Walker J, Mannel R . Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001; 81(2):273-8. DOI: 10.1006/gyno.2001.6157. View

13.

Takeshima N, Umayahara K, Fujiwara K, Hirai Y, Takizawa K, Hasumi K . Effectiveness of postoperative chemotherapy for para-aortic lymph node metastasis of endometrial cancer. Gynecol Oncol. 2006; 102(2):214-7. DOI: 10.1016/j.ygyno.2005.12.010. View

14.

Khuri S, Daley J, Henderson W . The comparative assessment and improvement of quality of surgical care in the Department of Veterans Affairs. Arch Surg. 2002; 137(1):20-7. DOI: 10.1001/archsurg.137.1.20. View

15.

Shah P, Kudrimoti M, Feddock J, Randall M . Adjuvant treatment for stage IIIC endometrial cancer: options and controversies. Gynecol Oncol. 2011; 122(3):675-83. DOI: 10.1016/j.ygyno.2011.05.018. View

16.

Rasool N, Fader A, Seamon L, Neubauer N, Abu Shahin F, Alexander H . Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2009; 116(1):10-4. DOI: 10.1016/j.ygyno.2009.10.043. View

17.

Kitchener H, Swart A, Qian Q, Amos C, Parmar M . Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2008; 373(9658):125-36. PMC: 2646126. DOI: 10.1016/S0140-6736(08)61766-3. View

18.

Randall M, Filiaci V, Muss H, Spirtos N, Mannel R, Fowler J . Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 24(1):36-44. DOI: 10.1200/JCO.2004.00.7617. View

19.

Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S . Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2007; 108(1):226-33. DOI: 10.1016/j.ygyno.2007.09.029. View

20.

McMeekin D, Lashbrook D, Gold M, Scribner D, Kamelle S, Tillmanns T . Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol. 2001; 82(2):375-9. DOI: 10.1006/gyno.2001.6278. View